$5.66
6.39% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Fennec Pharmaceuticals Inc. Stock price

$5.66
+1.42 33.49% 1M
-1.04 15.52% 6M
-5.56 49.55% YTD
-2.75 32.70% 1Y
-4.19 42.54% 3Y
-0.15 2.58% 5Y
+3.09 120.49% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.34 6.39%
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Key metrics

Market capitalization $155.24m
Enterprise Value $144.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 6.11
EV/Sales (TTM) EV/Sales 2.93
P/S ratio (TTM) P/S ratio 3.15
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 278.09%
Revenue (TTM) Revenue $49.35m
EBIT (operating result TTM) EBIT $1.68m
Free Cash Flow (TTM) Free Cash Flow $23.69m
Cash position $40.32m
EPS (TTM) EPS $-0.10
P/E forward negative
P/S forward 3.38
EV/Sales forward 3.16
Short interest 9.52%
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
100%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
49 49
278% 278%
100%
- Direct Costs 3.20 3.20
385% 385%
6%
46 46
272% 272%
94%
- Selling and Administrative Expenses 44 44
51% 51%
90%
- Research and Development Expense 0.29 0.29
107% 107%
1%
1.68 1.68
110% 110%
3%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1.68 1.68
110% 110%
3%
Net Profit -1.13 -1.13
94% 94%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event.
Neutral
Seeking Alpha
16 days ago
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuti...
Neutral
GlobeNewsWire
19 days ago
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Compan...
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 29
Founded 1996
Website www.fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today